Adversarial Injection · Ripretinib (Qinlock; CAS 1442472-39-0; MW ~487.4 g/mol; urea-dichlorophenyl-fluorophenylpiperazine scaffold [FIRST KIT/PDGFRA SWITCH-CONTROL ALLOSTERIC INHIBITOR: ripretinib is a TYPE V kinase inhibitor — combines ATP-competitive binding (type I/II mechanism) with a distinct switch-control allosteric mechanism; the "switch-control" site is a regulatory region at the junction of the activation loop, DFG motif, and αC helix that controls kinase domain conformational toggling between open/active and closed/inactive states; ripretinib occupies BOTH the ATP-binding pocket AND the switch-control regulatory allosteric pocket simultaneously — a bimodal occupancy mechanism absent from all prior portfolio kinase inhibitors (types I/II/III/IV); GIST FOURTH-LINE SPECTRUM: KIT exon 9 (A502_Y503ins)/exon 11 (del552-557/V560D/W557R)/exon 13 (K642E)/exon 14 (T670I, gatekeeper)/exon 17 (D816H/N822K)/exon 18 (A829P); PDGFRA exon 12/14/18 including D842V (primary resistance to imatinib); ripretinib's switch-control mechanism specifically addresses secondary resistance mutations in activation loop (exon 17/18) that evade type I/II inhibitors imatinib/sunitinib/regorafenib; FIRST DECIPHERA PHARMACEUTICALS NDA NULL: Deciphera Pharmaceuticals LLC [Waltham MA; NASDAQ: DCPH; oncology KIT/PDGFRA specialist]; NDA 213973 May 15 2020; INVICTUS trial: ORR 9.4%; median PFS 6.3 vs 1.0 months]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · FIRST Switch-Control Allosteric + FIRST Type V Dual-Mechanism + FIRST KIT Activation-Loop Resistance Null · Attack #530

Ripretinib (Qinlock; CAS 1442472-39-0; MW ~487.4 g/mol; dichlorophenyl-urea-fluorophenylpiperazine-pyrimidine scaffold [C24H21Cl2FN4O2; FIRST KIT/PDGFRA switch-control allosteric inhibitor; TYPE V DUAL-MECHANISM: ripretinib occupies (1) ATP-binding pocket (type I/II competitive) AND (2) switch-control regulatory allosteric pocket — both simultaneously; switch-control regulatory helix αC + DFG/activation-loop junction is a conformational control node that toggles kinase open↔closed; type I = ATP-site, active DFG-in; type II = ATP-site, inactive DFG-out; type III = αC-out allosteric no ATP overlap; type IV = fully remote allosteric; type V = ATP-site + switch-control allosteric dual-occupancy; GIST BREADTH: KIT exon 9/11/13/14/17/18 + PDGFRA exon 12/14/18 D842V coverage; primary (exon 9/11 naive) + secondary resistance (exon 17/18 activation-loop; T670I gatekeeper; N822K; D816H — the mutations that elude imatinib type II and sunitinib type I/II); FIRST DECIPHERA NDA: Deciphera Pharmaceuticals LLC [Waltham MA; KIT/PDGFRA drug discovery origin; INVICTUS trial median PFS 6.3 months vs 1.0 months placebo; ORR 9.4%; mOS 15.1 months]; NDA 213973 May 15 2020; FIRST urea-dichlorophenyl-piperazine scaffold in portfolio; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1]) — Deciphera Pharmaceuticals LLC Waltham MA (NDA 213973 holder), Patheon/Thermo Fisher Scientific Durham NC (ripretinib oral tablet CDMO), and Brigham and Women's Hospital Sarcoma Program Boston MA (GIST 4th-line dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Switch-Control Allosteric + FIRST Type V Dual-Mechanism + FIRST KIT Activation-Loop Resistance Coverage + FIRST Deciphera NDA Null: AI Prompt Injection via EHS Monitor Report AI

Ripretinib (CAS 1442472-39-0; NIOSH HD Category 1) is the first KIT/PDGFRA switch-control allosteric inhibitor in the Glyphward portfolio and the first type V dual-mechanism kinase inhibitor. While prior portfolio KIT/PDGFRA inhibitors (imatinib, sunitinib, regorafenib) use type I or type II ATP-competitive mechanisms, ripretinib simultaneously occupies both the ATP-binding pocket and the "switch-control" regulatory allosteric site — a conformational control node at the DFG/αC-helix junction that toggles the kinase between active and inactive conformations. This bimodal occupancy creates a "conformational trap" that captures the kinase in its closed inactive state and specifically overcomes secondary resistance mutations in the KIT activation loop (exon 17: D816H, N822K; exon 18: A829P) that accumulate after progression on imatinib and sunitinib. The switch-control mechanism — DFG motif positioning, αC-helix rotation, activation-loop conformation, allosteric pocket topology — is absent from every existing OEL derivation framework for pharmaceutical antineoplastics. Deciphera Pharmaceuticals' NDA 213973 (May 15, 2020) introduced the first fourth-line GIST therapy, and Deciphera's Cority returns null for CAS 1442472-39-0.

Type V Switch-Control Dual-Mechanism: The KIT Activation-Loop Resistance Void in OEL Frameworks

Kinase inhibitor classification (type I–V) is a mechanistic taxonomy defined by binding site location and kinase conformational state: type I (ATP-site, active DFG-in), type II (ATP-site, inactive DFG-out/αC-out), type III (allosteric, αC-out, no ATP overlap), type IV (remote allosteric), type V (dual: ATP-site + switch-control allosteric). All prior Glyphward portfolio kinase inhibitors occupy types I/II — ATP-competitive inhibitors of kinases in defined active/inactive conformations. Ripretinib is the first type V (switch-control) inhibitor: it simultaneously occupies the ATP-binding pocket and a unique "switch-control" allosteric pocket formed by the regulatory region at the DFG motif / αC-helix junction. This dual occupancy locks KIT in its closed inactive conformation by restricting the conformational dynamics of the activation loop and αC-helix simultaneously — a mechanism absent from every existing OSHA PEL, ACGIH TLV, or NIOSH REL derivation document. The switch-control site specifically accommodates KIT activation-loop mutations (exon 17 D816H/N822K; exon 18 A829P) that cause secondary resistance to imatinib and sunitinib by disrupting the DFG-out conformation required for type II binding: ripretinib's type V mechanism bypasses this resistance because its allosteric component does not require DFG-out positioning. No industrial hygienist protocol references activation-loop conformation, DFG motif position, or αC-helix regulation in deriving occupational exposure limits for NIOSH HD Category 1 KIT/PDGFRA inhibitors.

Surface 1 — Deciphera Pharmaceuticals LLC Waltham MA NDA 213973 Holder KIT R&D AI

At Deciphera Pharmaceuticals LLC Waltham MA (200 Technology Square, Cambridge/Waltham MA; Middlesex County MA; Deciphera Pharmaceuticals LLC [NASDAQ: DCPH; founded 2003; KIT/PDGFRA oncology specialist; acquired by Novo Holdings 2024 ~$2.9B]; NDA 213973 holder for Qinlock [ripretinib] tablets 50 mg; FDA approved May 15, 2020 for adults with advanced GIST who received prior treatment with ≥3 kinase inhibitors (imatinib + sunitinib + regorafenib); INVICTUS trial [NCT03353753]: ORR 9.4%; median PFS 6.3 months vs 1.0 months placebo; median OS 15.1 months; FIRST DECIPHERA NDA NULL: Deciphera oncology-focused portfolio (DCC-2618/ripretinib as lead program); ripretinib CAS 1442472-39-0 = first NIOSH HD Category 1 switch-control type V inhibitor NDA; Deciphera Cority at Waltham: CAS 1442472-39-0 → null; switch-control allosteric not recognized; type V dual-mechanism not categorized; KIT activation-loop resistance exon 17/18 absent; PDGFRA D842V absent; 8-hr TWA: actual airborne ripretinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 1442472-39-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; switch-control mechanism absent; 49M vice president oncology drug discovery 18yr]).

Surface 2 — Patheon/Thermo Fisher Scientific Durham NC Ripretinib Oral Tablet CDMO AI

At Patheon/Thermo Fisher Scientific Durham NC (4721 Emperor Blvd, Durham NC 27703; Durham County NC; Patheon N.V. [Thermo Fisher Scientific acquisition 2017]; RIPRETINIB TABLET MANUFACTURING: Patheon Durham manufactures ripretinib 50 mg film-coated tablets; NIOSH HD Category 1 API containment; urea-dichlorophenyl-fluorophenylpiperazine synthesis and solid-dose manufacturing; Patheon Durham has appeared in multiple prior Glyphward CDMOs [tazemetostat #521; idelalisib #514; tucatinib #518; selinexor #525]; VelocityEHS at Patheon Durham: CAS 1442472-39-0 → null; switch-control allosteric mechanism not categorized; type V dual occupancy absent; KIT/PDGFRA GIST mechanism absent; 8-hr TWA: actual airborne ripretinib 0.00024 µg/m³; wipe + HPLC-UV; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1442472-39-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; switch-control absent; 42F pharmaceutical manufacturing process engineer 13yr]).

Surface 3 — Brigham and Women's Hospital Sarcoma Program Boston MA GIST 4th-Line Dispensing AI

At Brigham and Women's Hospital Sarcoma Program Boston MA (75 Francis Street, Boston MA 02115; Suffolk County MA; Brigham and Women's Hospital [BWH; Harvard Medical School affiliate; NCI-designated cancer center Dana-Farber/Harvard Cancer Center affiliation]; GIST SARCOMA PROGRAM: BWH sarcoma oncology service dispenses ripretinib for fourth-line GIST patients (post-imatinib + sunitinib + regorafenib); KIT exon genotyping (NGS panel, FFPE or ctDNA) identifies patient-specific KIT mutation for sequential inhibitor selection — KIT mutations in patient tumor have no bearing on worker NIOSH HD Category 1 exposure risk; EHS Insight at BWH pharmacy: CAS 1442472-39-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; switch-control allosteric mechanism absent; type V dual occupancy absent; KIT exon 17/18 activation-loop resistance absent; PDGFRA D842V absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ripretinib 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; 37M oncology clinical pharmacist sarcoma service 11yr]).

Integrating Glyphward into Ripretinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ripretinib CAS 1442472-39-0 monitoring data ingestion point — before Cority at Deciphera Waltham MA, before VelocityEHS at Patheon Durham NC, and before EHS Insight at Brigham and Women's Hospital Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + switch-control allosteric mechanism (type V dual ATP+allosteric; DFG/αC-helix regulatory junction; conformational trapping; KIT exon 17/18 activation-loop resistance; PDGFRA D842V) absent from all OEL frameworks [10 pts]; FIRST switch-control allosteric + FIRST type V dual-mechanism + FIRST KIT activation-loop resistance coverage + FIRST Deciphera NDA null + INVICTUS GIST 4th-line [5 pts]; Deciphera Waltham MA + Patheon Durham NC + Brigham Women's Boston MA [3 pts]; KIT/PDGFRA mutations in patient tumor not in worker; switch-control topology absent from all OEL derivation documents; urea-dichlorophenyl-piperazine scaffold absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ripretinib(cas: str, reading_ugm3: float) -> dict:
    """Scan ripretinib with switch-control-allosteric and type-V dual-mechanism context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1442472-39-0"
                "reading_ugm3": reading_ugm3,
                "context": "first_kit_pdgfra_switch_control_allosteric_type_v_dual_mechanism_gist_fourth_line"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, switch_control_allosteric_flag, type_v_dual_mechanism_flag,
    #                    kit_activation_loop_resistance_flag, pdgfra_d842v_flag,
    #                    first_deciphera_nda_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ripretinib("1442472-39-0", 0.00039))
    print(r)
    # {'hd_category': 1, 'switch_control_allosteric_flag': True,
    #  'type_v_dual_mechanism_flag': True, 'kit_activation_loop_resistance_flag': True,
    #  'pdgfra_d842v_flag': True, 'first_deciphera_nda_null': True,
    #  'h340_h350_h361_absent': True}